Concepedia

Farshid Dayyani

FD

Statistics

Publications

51

Citations

4.8K

H-Index

30

Active since

2000

Affiliations

University of California, Irvine(Current)

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Ludwig-Maximilians-Universität München

Natera (United States)

Farshid Dayyani is an author at University of California, Irvine specializing in oncology, medicine, and molecular oncology.

Publications per year

2000–2025

51

Publications

51

The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF

Kai-Uwe Belge, Farshid Dayyani, Alexia Horelt et al. · The Journal of Immunology · 2002 · 876 citations · Full text

Life Sciences, Cell Biology, Immunology +13

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta et al. · Nature Medicine · 2022 · 627 citations

Medicine, Oncology, Pharmacology +16

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Muling Mao, Feng Tian, John M. Mariadason et al. · Clinical Cancer Research · 2012 · 298 citations

Medicine, Oncology, Pharmacology +17

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour et al. · The Lancet. Gastroenterology & hepatology · 2024 · 254 citations · Full text

Medicine, Oncology, Pharmacology +11

1–5 of 51